{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23439.7","value":"20345.6"},{"groupId":"OG001","spread":"15559.2","value":"12780.0"},{"groupId":"OG002","spread":"20919.7","value":"19502.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Blood blast cells: CR/CRi"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2397.1","value":"31080.0"},{"comment":"SD cannot be calculated for a single participant.","groupId":"OG001","spread":"NA","value":"22952.0"},{"groupId":"OG002","spread":"4203.0","value":"9815.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Blood blast cells: Non CR/CRi;"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3018.6","value":"13506.2"},{"groupId":"OG001","spread":"1796.1","value":"22639.0"},{"groupId":"OG002","spread":"3764.6","value":"11220.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Blood immune cells (Natural Killer [NK] cells): CR/CRi"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"851.4","value":"16650.0"},{"comment":"SD cannot be calculated for a single participant.","groupId":"OG001","spread":"NA","value":"33859.0"},{"groupId":"OG002","spread":"685.9","value":"22530.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Blood immune cells (NK cells): Non CR/CRi"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"description":"Blood samples were collected to assess CD38 receptor density as a predictive biomarker. It was assessed across complete responders and non-complete responders. The Antibody Binding Capacity (ABC) was calculated using the following equation: ABC = 10\\^(Logarithm(Mean Fluorescence Intensity)\\*a+b) where \"a\" was the slope and \"b\" was the Y-intercept of the calibration curve equation. Specific and absolute quantitative values (specific antibody-binding capacity \\[sABC\\]) of binding of the selected antibodies were calculated after subtraction of the negative isotypic immunoglobulin G (IgG) control.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with B-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG000","title":"B-cell Acute Lymphoblastic Leukemia (B-ALL)"},{"description":"Participants with T-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG001","title":"T-cell Acute Lymphoblastic Leukemia (T-ALL)"},{"description":"Participants with AML received isatuximab 20 mg/kg IV infusion on Days 1, 8, and 15 of each Cycle (up to 2 treatment cycles, each cycle 28 days). Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG002","title":"Acute Myeloid Leukemia (AML)"}],"paramType":"MEAN","populationDescription":"The evaluable population consisted of evaluable participants from the AT population who received at least 1 full dose of isatuximab in Cycle 1 and who had at least 1 valid response value that was evaluable. Only those participants with data available at specified timepoints were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1","title":"Cluster of Differentiation (CD)38 Receptor Density","type":"SECONDARY","unitOfMeasure":"sABC"}